Chemomab Therapeutics Ltd Stock Buy Hold or Sell Recommendation
| CMMB Stock | USD 0.68 0.02 2.86% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Chemomab Therapeutics Ltd is 'Hold'. Macroaxis provides Chemomab Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding CMMB positions. The advice algorithm takes into account all of Chemomab Therapeutics' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Chemomab Therapeutics' buy or sell advice are summarized below:
Real Value 2.25 | Target Price 7 | Hype Value 0.74 | Market Value 0.68 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Chemomab Therapeutics Ltd given historical horizon and risk tolerance towards Chemomab Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Chemomab Therapeutics Ltd, the advice is generated through an automated system that utilizes algorithms and statistical models.
Chemomab |
Execute Chemomab Therapeutics Buy or Sell Advice
The Chemomab recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Chemomab Therapeutics Ltd. Macroaxis does not own or have any residual interests in Chemomab Therapeutics Ltd or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Chemomab Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Sell
Market Performance | OK | Details | |
Volatility | Very risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Chemomab Therapeutics Trading Alerts and Improvement Suggestions
| Chemomab Therapeutics is way too risky over 90 days horizon | |
| Chemomab Therapeutics has some characteristics of a very speculative penny stock | |
| Chemomab Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (24.16 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Chemomab Therapeutics Ltd currently holds about 51.72 M in cash with (23.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.53, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 15.0% of the company shares are held by company insiders | |
| Latest headline from globenewswire.com: Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis |
Chemomab Therapeutics Returns Distribution Density
The distribution of Chemomab Therapeutics' historical returns is an attempt to chart the uncertainty of Chemomab Therapeutics' future price movements. The chart of the probability distribution of Chemomab Therapeutics daily returns describes the distribution of returns around its average expected value. We use Chemomab Therapeutics Ltd price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Chemomab Therapeutics returns is essential to provide solid investment advice for Chemomab Therapeutics.
| Mean Return | 0.47 | Value At Risk | -5.19 | Potential Upside | 9.23 | Standard Deviation | 4.93 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Chemomab Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Chemomab Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Chemomab Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Chemomab Therapeutics Ltd backward and forwards among themselves. Chemomab Therapeutics' institutional investor refers to the entity that pools money to purchase Chemomab Therapeutics' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Advisory Services Network, Llc | 2023-12-31 | 4.8 K |
Chemomab Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Chemomab Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Chemomab Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Chemomab stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.34 | |
β | Beta against NYSE Composite | 1.52 | |
σ | Overall volatility | 5.03 | |
Ir | Information ratio | 0.08 |
Chemomab Therapeutics Volatility Alert
Chemomab Therapeutics Ltd shows above-average downside volatility for the selected time horizon. Chemomab Therapeutics Ltd is a potential penny stock. Although Chemomab Therapeutics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Chemomab Therapeutics Ltd. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Chemomab instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Chemomab Therapeutics Fundamentals Vs Peers
Comparing Chemomab Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Chemomab Therapeutics' direct or indirect competition across all of the common fundamentals between Chemomab Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Chemomab Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Chemomab Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Chemomab Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Chemomab Therapeutics to competition |
| Fundamentals | Chemomab Therapeutics | Peer Average |
| Return On Equity | -0.91 | -0.31 |
| Return On Asset | -0.49 | -0.14 |
| Current Valuation | 173.79 M | 16.62 B |
| Shares Outstanding | 14.2 M | 571.82 M |
| Shares Owned By Insiders | 14.99 % | 10.09 % |
| Shares Owned By Institutions | 24.96 % | 39.21 % |
| Number Of Shares Shorted | 221.87 K | 4.71 M |
| Price To Book | 0.64 X | 9.51 X |
| EBITDA | (25.33 M) | 3.9 B |
| Net Income | (24.16 M) | 570.98 M |
| Cash And Equivalents | 51.72 M | 2.7 B |
| Cash Per Share | 4.53 X | 5.01 X |
| Total Debt | 392 K | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 12.48 X | 2.16 X |
| Book Value Per Share | 1.20 X | 1.93 K |
| Cash Flow From Operations | (23.55 M) | 971.22 M |
| Short Ratio | 2.14 X | 4.00 X |
| Earnings Per Share | (2.06) X | 3.12 X |
| Target Price | 7.0 | |
| Beta | -0.044 | -0.15 |
| Market Capitalization | 9.66 M | 19.03 B |
| Total Asset | 22.15 M | 29.47 B |
| Retained Earnings | (88.68 M) | 9.33 B |
| Working Capital | 16.06 M | 1.48 B |
| Net Asset | 22.15 M |
Note: Insider Trading [view details]
Chemomab Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Chemomab . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Chemomab Therapeutics Buy or Sell Advice
When is the right time to buy or sell Chemomab Therapeutics Ltd? Buying financial instruments such as Chemomab Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Total Current Liabilities | 2.7M | 6.7M | 4.8M | 3.8M | Other Current Liabilities | 1.2M | 4.9M | 4.2M | 2.9M |
Use Investing Ideas to Build Portfolios
In addition to having Chemomab Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Consumption Thematic Idea Now
Consumption
Companies that deliver final goods such as cars or clothing for consumption by consumers. The Consumption theme has 18 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumption Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Chemomab Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Chemomab Stock analysis
When running Chemomab Therapeutics' price analysis, check to measure Chemomab Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chemomab Therapeutics is operating at the current time. Most of Chemomab Therapeutics' value examination focuses on studying past and present price action to predict the probability of Chemomab Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chemomab Therapeutics' price. Additionally, you may evaluate how the addition of Chemomab Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is Chemomab Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chemomab Therapeutics. If investors know Chemomab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chemomab Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.06) | Return On Assets (0.49) | Return On Equity (0.91) |
The market value of Chemomab Therapeutics is measured differently than its book value, which is the value of Chemomab that is recorded on the company's balance sheet. Investors also form their own opinion of Chemomab Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Chemomab Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chemomab Therapeutics' market value can be influenced by many factors that don't directly affect Chemomab Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chemomab Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Chemomab Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chemomab Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.